Category: Regulatory DisclosuresBy adminApril 1, 2020 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:EGX disclosure regarding the postponement of the OGMNextNext post:Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda) S.A.E. Acquires A Large Generic Product in a Sizable and Fast-Growing Therapeutic AreaRelated PostsBOD-Shareholding-Structure-2024April 15, 2024The invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024Rameda 4Q23 BOD Meeting MinutesMarch 18, 2024BOD Report FY2023- under the Regulatory DisclosuresMarch 18, 2024Annual Corporate Governance Disclosure ReportMarch 18, 2024
